Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis

Journal of B.U.ON.

Volumn 14, Issue 2, 2009, Pages 259-264

  Spiliotis, John D ^a,c   Rogdakis, A ^a   Vaxevanidou, A ^a   Datsis, A ^a   Zacharis, G ^a   Christopoulou, A ^b  

^a Mesolongi General Hospital   (Greece)

^b UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^c NONE   (Greece)

Author keywords

Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal carcinomatosis

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER MORTALITY; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM FISTULA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; LUNG DISEASE; MORBIDITY; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY;

EID: 67651055950     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Gusani N, Cho S, Colovos Ch et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008; 15: 754-763.
2. Elias D, Goere D, Blot F et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43°C after complete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol 2007; 14: 1818-1824. (Pubitemid 46870938)
3. Spiliotis J, Tentes AA, Vaxevanidou A et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece. J BUON 2008; 13: 205-210. (Pubitemid 351836702)
4. Sugarbaker P, Alderman R, Edwards G et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006; 3: 635-644.
5. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res 2007; 134: 247-264.
6. Glehen O, Osinsky D, Beaujard AC, Gilly FN. Natural history of peritoneal carcinomatosis from non gynecologic malignancies. Surg Oncol Clin N Am 2003; 12: 729-739. (Pubitemid 36920095)
7. Feldman AL, Libutti SK, Pingpank JF et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21: 4560-4567.
8. Shen P, Levine EA, Hall J et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138: 26-35. (Pubitemid 36055643)
9. Deraco M, Baratti D, Inglese MG et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11: 393-398. (Pubitemid 40486749)
10. Elias D, Blot F, El Otmany A et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92: 71-76. (Pubitemid 32623042)
11. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43: 515-525.
12. Glehen O, Osinsky D, Cotte E et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10: 863-869. (Pubitemid 40486849)
13. Kusamura S, Younan R, Boratti D et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006; 106: 1144-1153. (Pubitemid 43297355)
14. Stephens AD, Alderman R, Chang D et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999; 6: 790-796. (Pubitemid 30013658)
15. Witkamp AJ, deBree E, Van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27: 365-374.
16. Kecmanovic DM, Pavlor MJ, Ceranic MS et al. Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreduction and hyperthermic perioperative intraperitoneal chemotherapy. Eur J Surg Oncol 2005; 31: 147-152. (Pubitemid 40214749)
17. Verwaal J, van Tinteren H, Ruth SV, Zoetmulder FAN. Toxicity of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2004; 85: 61-67. (Pubitemid 38160772)
18. Schmidt U, Dahlke M, Klempnauer J et al. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005; 31: 53-58. (Pubitemid 40103925)
19. Roviello F, Marrelli D, Neri A et al. Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion: postoperative outcome and risk factors for morbidity. World J Surg 2006; 30: 2033-2040. (Pubitemid 44655812)
20. Moran BJ, Meade B, Murphy E. Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis of colorectal origin: a novel treatment strategy with promising results in selected patients. Colorectal Dis 2006; 8: 544-550. (Pubitemid 44210104)
21. Smeenk RM, Verwaal VJ, Zoetmulder FAN. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei - a report of 103 procedures. Eur J Surg Oncol 2006; 32: 186-190.
22. Levine EA, Stewart J, Russel G et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg 2007; 204: 943-953.